Cannabinoid agonists differentially substitute for the discriminative stimulus effects of Δ9-tetrahydrocannabinol in C57BL/6J mice
- 3 August 2007
- journal article
- research article
- Published by Springer Nature in Psychopharmacology
- Vol. 198 (4) , 487-495
Abstract
Rationale A variety of behavioral procedures have been developed to assess cannabinoid activity in mice; however, the feasibility of establishing Δ9-THC as a discriminative stimulus in mice has not been documented. Objective One goal was to establish Δ9-THC as a discriminative stimulus in mice; after having done so, another goal was to examine the in vivo mechanism of action of Δ9-THC with other cannabinoids and noncannabinoids. Materials and methods C57BL/6J mice (n = 8) were trained to discriminate Δ9-THC (10 mg/kg i.p.) from vehicle while responding under a fixed ratio 30 schedule of food presentation. Results Mice satisfied the discrimination criteria in 18–98 (median = 67) sessions and the discriminative stimulus effects of Δ9-THC were dose-dependent (ED50 = 2.6 mg/kg). CP 55940 and WIN 55212-2 dose-dependently increased Δ9-THC-appropriate responding to 100% (ED50 = 0.032 and 0.45 mg/kg, respectively), whereas methanandamide and a variety of noncannabinoids (cocaine, ethanol, and ketamine) produced a maximum of 34% Δ9-THC-appropriate responding. The cannabinoid CB1 antagonist SR 141716A (rimonabant) surmountably antagonized the discriminative effects of Δ9-THC, CP 55940, and WIN 55212-2; methanandamide did not significantly modify the Δ9-THC discriminative stimulus. Conclusions The discriminative stimulus effects of Δ9-THC, CP 55940, and WIN 55212-2 are mediated by the same (i.e., CB1) receptors, whereas the effects of methanandamide or a metabolite of methanandamide are mediated at least in part by non-CB1 receptors. The discriminative stimulus effects of Δ9-THC in mice could be used to evaluate mechanisms of cannabinoid activity with approaches (e.g., inducible knockouts) currently unavailable in nonmurine species.Keywords
This publication has 35 references indexed in Scilit:
- Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J miceEuropean Journal of Pharmacology, 2007
- Characterization of Cannabinoid Agonists and Apparent p A2 Analysis of Cannabinoid Antagonists in Rhesus Monkeys Discriminating Δ9-TetrahydrocannabinolThe Journal of Pharmacology and Experimental Therapeutics, 2006
- Activation of G-proteins in brain by endogenous and exogenous cannabinoidsThe AAPS Journal, 2006
- Characterization of the Fatty Acid Amide Hydrolase Inhibitor Cyclohexyl Carbamic Acid 3′-Carbamoyl-biphenyl-3-yl Ester (URB597): Effects on Anandamide and Oleoylethanolamide DeactivationThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Differential Effects of Δ9-Tetrahydrocannabinol and Methanandamide in CB1 Knockout and Wild-Type MiceThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Cannabinoid pharmacological properties common to other centrally acting drugsEuropean Journal of Pharmacology, 2003
- International Union of Pharmacology. XXVII. Classification of Cannabinoid ReceptorsPharmacological Reviews, 2002
- (R)-methanandamide, but not anadamide, substitutes for Δ–9-THC in a drug-discrimination procedure.Experimental and Clinical Psychopharmacology, 1997
- (R)-methanandamide, but not anadamide, substitutes for Δ-9-THC in a drug-discrimination procedure.Experimental and Clinical Psychopharmacology, 1997
- Pharmacological specificity of the discriminative stimulus effects of Δ9-tetrahydrocannabinol in rhesus monkeysDrug and Alcohol Dependence, 1995